GFAP and Cognitive impairment: These results suggest that a combination of brief cognitive testing, plasma Aβ42/Aβ40 ratio and GFAP level, along with age, sex, and APOE stratum, could help primary care providers better identify patients eligible for treatment among those with evidence of cognitive impairment.